

Educational Case: *Pseudomonas* and *Acinetobacter* Sepsis Due to Thermal Injury

Behnam Sobouti^{1,*}, Yaser Ghavami¹, Shahrzad Fallah¹

¹Burn and Reconstructive Research Center, Shahid Motahari Burns Hospital, Iran University of Medical Sciences, Tehran, IR Iran

*Corresponding author: Shahid Motahari Burns Hospital, Vali-asr Avenue, Yasami St., Tehran, IR Iran, Tel.: +98-2188770031, Fax: +98-2188770048, E-mail: bso-booti@tums.ac.ir.

ABSTRACT

Background: Multi drug resistant (MDR) *Pseudomonas* and *Acinetobacter* species are defined as resistant to at least three classes of antibiotics. Most studies have demonstrated that MDR gram negative infections convey increased mortality and morbidity.

Case: An 11-year-old girl was admitted to pediatric burns unit with burn injury of approximately 68% total body surface area (TBSA).

Discussion: Role of systemic antibiotics is adjunctive and never replaces surgical debridement, use of topical agents, nutritional support, increasing in immune system function and grafting. Evidence in the published literature suggests that combination therapy with Meropenem and Colistin are effective for burned patients with MDR gram negative sepsis.

Keywords: Drug Resistant, Multiple; Sepsis; Colistin

Copyright © 2013, Kowsar Corp.; Published by Kowsar Corp.

1. Introduction

Improvements in treatment of burn patients have been dramatic in recent years, although associated infections lead to increased mortality in these patients. Immunodeficiency status of the patient and virulence characteristic of pathogenic agent are the main factors that can cause infections in these patients. Both cell mediated and humoral immunity have great effects on infection in burn patient (1).

Multi drug resistant (MDR) *Pseudomonas* and *Acinetobacter* are defined as resistant to at least three classes of antibiotics. Most studies have demonstrated that MDR gram negative infections convey increased mortality, longer hospital stays and higher hospital costs when compared with infections associated with susceptible strains (2, 3). Sepsis and related problems are the major cause of death in burns patients and represent an outstanding problem also in view of the emergence of MDR organisms (4).

►Article type: Case Report; Received: 18 Dec 2012, Revised: 27 Dec 2012, Accepted: 06 Apr 2013; DOI: 10.5812/pedinfect.9848

►Implication for health policy/practice/research/medical education:

MDR (Multi drug resistant) *Pseudomonas* species and *Acinetobacter* species are defined as resistant to at least three classes of antibiotics. Our patient was treated with systemic antibiotics, topical agents, novel dressing, G-CSF and IVIG. Systemic antibiotics are only used when systemic infection is strongly suspected, but its role is adjunctive and it never replaces surgical debridement, and grafting. Evidence in the published literature suggests that this combination therapy is effective for burned patients with MDR gram negative sepsis.

►Please cite this paper as:

Sobouti B, Ghavami Y, Fallah S. Educational Case: *Pseudomonas* and *Acinetobacter* Sepsis Due to Thermal Injury. Arch Pediatr Infect Dis. 2013;1(3): 147-50. DOI: 10.5812/pedinfect.9848

►Copyright © 2013, Kowsar Corp.; Published by Kowsar Corp.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/3.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

2. Case Description

An 11-year-old girl was admitted to pediatric burns unit with a history of thermal injury. She was transferred to our burns unit for definitive management. She had sustained approximately 68% total body surface area (TBSA) affecting her posterior trunk, upper and lower limbs. Full thickness injury mainly affected her posterior trunk (Figure 1).



Figure 1. Photograph Showing Full Thickness Injury Mainly Affecting Posterior Trunk

After initial fluid resuscitation, supportive care and first debridement, on the sixth day, she had developed sudden tachycardia, tachypnea and high grade fever. Over a period of 3-4 days, sepsis progressed to severe form and septic shock. Routine blood tests showed leukopenia (neutropenia), thrombocytopenia, elevated liver enzymes, elevated fibrinogen deposit product (FDP) and d-dimer. Blood gas analysis showed severe metabolic acidosis. Serum immunoglobulin levels especially IgG1 and IgG2 subclasses were decreased. Serum creatinine, prothrombin time (PT) and partial thromboplastin time (PTT) were elevated. Urine analysis and serum electrolytes were within normal limits. Blood and wound cultures were positive for multi-drug resistant (MDR) *Pseudomonas aeruginosa* and the central venous catheter culture was positive for *Acinetobacter baumannii*. Tissue culture was positive for MDR *Pseudomonas aeruginosa* $> 10^5$ CFU per gram tissue. Radiological investigations with chest x-rays reveal acute respiratory distress syndrome (ARDS) appearance.

In this situation, the patient was treated with systemic antibiotics including Teicoplanin (gram positive organisms are dominant in the early days of burn injury) and Meropenem, topical agents, novel dressing, granulocyte colony stimulating factor (G-CSF) and intravenous immunoglobulin (IVIG). After clarification of culture results,

Teicoplanin was stopped and treatment with Tobramycin and Colistin started. She was managed with packed cells, fresh frozen plasma, platelet and cryoprecipitate. Ventilatory support was done. Nutritional supports especially zinc, glutamine, multivitamins, albumin and aminofusion had very important roles in patient management. After five days, the patient's general condition was better than last days (Figure 2).

She underwent multiple debridement of all the wounds which were covered with skin grafting from multiple donor sites (Figure 3). She made a full recovery and was discharged 9 weeks later.

3. Discussion

In different investigations, the mortality rate due to MDR *Pseudomonas* and *Acinetobacter* infections among burn patients has been reported as 30 to 38%. In comparison to this high mortality rate reported in the literature, the survival of our case is notable and wonderful (5). In a study by Azimi et al., it was shown that comorbidity of *Pseudomonas* and *Acinetobacter* infection causes longer hospital stay and increased mortality in burn patients (6). The most reliable predictor of outcome of pediatric burns is the percentage of TBSA burned, followed by depth. The enormous progress in burn treatment is attributable to the multiple factors including knowledge of the pathophysiology of burns, recognition of the importance of nutritional needs, use of topical agents/novel dressing/systemic antibiotics, increasing in immune system and early debridement/grafting techniques. For a child with a disrupted mechanical barrier and suppressed immune system, any organism is a potential pathogen (7).

Multi-drug resistant *Pseudomonas* and *Acinetobacter* species are defined as resistant to at least three classes of antibiotics. The number of organisms present on the burn wound, organism's unique virulence, invasiveness and motility affect pathogenicity. In a study by Goverman et al., they identified 14 children infected with pan-resistant gram negative organisms that were treated by 16 courses of Colistin. 12 (85.7%) cases had a favorable response to therapy; however 2 (14.3%) cases died due to sepsis (8). Ferreira et al. reported that nowadays resistance in *Pseudomonas* and *Acinetobacter* species have been a growing problem in burn patients and antibacterial therapy has been frequently associated with resistance. Also they indicated that prevention of cross-transmission is an important factor in controlling resistance for these patients (9).

The patient's blood cultures with BACTEC method showed *Pseudomonas aeruginosa* that was resistant to Aztreonam, Cefepime, Amikacin and Ciprofloxacin. The isolate was sensitive to Tobramycin, Meropenem and Colistin.



Figure 2. Photograph Showing Wound Appearance Was Better Than Last Days. Novel painless dressing with ENTONOX mask is shown in this picture.



Figure 3. Photograph Showing Skin Grafting from Multiple Donor sites

Colistin is a polypeptide antibiotic of the Polymyxin group that is rapidly bactericidal to gram negative bacteria. This

drug has a detergent-like mechanism interfering with the outer cytoplasmic membrane of the bacteria. Colistin remains active against almost all strains of *Pseudomonas* and *Acinetobacter*. Acquired resistance is rare. Colistin seems to be a safe drug in selected cases of infections with MDR gram negative micro-organisms (10). In a study by Tamma et al., they found out that Colistin application was safe. Although there was some evidence of nephrotoxicity and neurotoxicity in some patients, but these adverse effects are reversible and rare (11).

In the study by Keen et al., it was reported that percentage of TBSA and other clinical parameters have influence on empiric antibiotic therapy and management of patients with multidrug resistant *Pseudomonas* and *Acinetobacter* (12).

Systemic antibiotics are only used when systemic infection is strongly suspected, but its role is adjunctive and it never replaces surgical debridement, use of topical agents, nutritional support, increasing in immune system function (IVIg/G-CSF/IFN- γ) and grafting. Evidence in the published literature suggests that this combination therapy is effective for burned patients with MDR gram negative sepsis (13).

Considering the present study, it is believed that an early diagnosis of the wound infection, administration of the appropriate systemic and topical antibiotics, early excision and grafting, adoption of infection control and prevention standards like proper hand hygiene, isolation rooms, environmental cleanliness and disinfection methods may significantly reduce infections caused by MDR micro-organisms in burn units. Also the pattern of resistance to antibiotics is an important factor in treatment, and using new antibiotics can be useful.

Acknowledgements

Authors wish to thank laboratory staffs working at Shahid Motahari Burn Hospital.

Authors' Contribution

B Sobouti: study designer, writer, editor and final approval, Y Ghavami: Editor and approval, Sh Fallah: Data collector and Editor

Financial Disclosure

Authors indicate that there is not any financial disclosure.

Funding/Support

Authors indicate that this study is not supported by any person or organization.

References

1. Sobouti B, Fallah S, Ghavami Y, Moradi M. Serum immunoglobulin

- lin levels in pediatric burn patients. *Burns*. 2013;**39**(3):473-6.
2. Glasser JS, Guymon CH, Mende K, Wolf SE, Hospenhal DR, Murray CK. Activity of topical antimicrobial agents against multidrug-resistant bacteria recovered from burn patients. *Burns*. 2010;**36**(8):1172-84.
3. Manchanda V, Sanchaita S, Singh N. Multidrug resistant acinetobacter. *J Glob Infect Dis*. 2010;**2**(3):291-304.
4. Mahar P, Padiglione AA, Cleland H, Paul E, Hinrichs M, Wasiak J. *Pseudomonas aeruginosa* bacteraemia in burns patients: Risk factors and outcomes. *Burns*. 2010;**36**(8):1228-33.
5. Selcuk Caferi Tayyar, Bozkurt Mehmet, Kuvat Samet Vasfi, Tekin Alicem, Tekin Recep, Kapi Emin. An Evaluation of Burn Infections Caused by Multidrug Resistant *A. baumannii* and the Treatment Approach. *J Current Surg*. 2011;**1**(1):7-11.
6. Azimi L, Motevallian A, Ebrahimzadeh Namvar A, Asghari B, Lari AR. Nosocomial infections in burned patients in motahari hospital, tehran, iran. *Dermatol Res Pract*. 2011;**2011**:436952.
7. Greenhalgh DG, Saffle JR, Holmes JH, Gamelli RL, Palmieri TL, Horton JW, et al. American Burn Association consensus conference to define sepsis and infection in burns. *J Burn Care Res*. 2007;**28**(6):776-90.
8. Goverman J, Weber JM, Keaney TJ, Sheridan RL. Intravenous colistin for the treatment of multi-drug resistant, gram-negative infection in the pediatric burn population. *J Burn Care Res*. 2007;**28**(3):421-6.
9. Ferreira AC, Gobara S, Costa SE, Sauaia N, Mamizuka EM, van der Heijden IM, et al. Emergence of resistance in *Pseudomonas aeruginosa* and *Acinetobacter* species after the use of antimicrobials for burned patients. *Infect Control Hosp Epidemiol*. 2004;**25**(10):868-72.
10. Rosanova M, Epelbaum C, Noman A, Villasboas M, Alvarez V, Berberian G, et al. Use of colistin in a pediatric burn unit in Argentina. *J Burn Care Res*. 2009;**30**(4):612-5.
11. Tamma PD, Newland JG, Pannaraj PS, Metjian TA, Banerjee R, Gerber JS, et al. The use of intravenous colistin among children in the United States: results from a multicenter, case series. *Pediatr Infect Dis J*. 2013;**32**(1):17-22.
12. Keen EF, 3rd, Robinson BJ, Hospenhal DR, Aldous WK, Wolf SE, Chung KK, et al. Prevalence of multidrug-resistant organisms recovered at a military burn center. *Burns*. 2010;**36**(6):819-25.
13. Shorr AF. Review of studies of the impact on Gram-negative bacterial resistance on outcomes in the intensive care unit. *Crit Care Med*. 2009;**37**(4):1463-9.